PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
3110.63%
G&A growth above 1.5x GNPX's 52.68%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
11227.11%
Total costs growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
26362.71%
Interest expense change of 26362.71% while GNPX maintains costs. Bruce Berkowitz would investigate control.
-84.19%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-40.83%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Other expenses reduction while GNPX shows 46.73% growth. Joel Greenblatt would examine advantage.
-16129.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense change of 155593.20% while GNPX maintains burden. Bruce Berkowitz would investigate strategy.
-16129.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
-12933.18%
Diluted EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
24.22%
Share count reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.
24.22%
Diluted share reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.